Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus.
The proportion of cancer patients candidate to receive immune checkpoint inhibitors (ICI) as part of the therapeutic approach is increasing in all settings, from the early to the advanced stage of disease. The management of ICI in special populations of patients with viral hepatitis or autoimmune disease still lacks strong evidence-based recommendations. Patients having one of these two clinical conditions are generally excluded from clinical trials testing immunotherapic compounds. We present the experience of a patient with heavily pretreated advanced non-small-cell lung cancer affected by both chronic active hepatitis C and systemic lupus erythematosus, treated with nivolumab. We give a report of long-term efficacy and safety data, and we provide an insight on this important topic.